Fig 1: MiR-877-5p exhibits tumor-suppressive roles via targeting SSFA2. PC3 cells were transfected with miR-877-5p mimic and/or pc-SSFA2. A,B) SSFA2 mRNA and protein levels. C) CCK-8 cell viability. D) EdU incorporation assay. E) wound-healing assay. F) Transwell invasion assay. G) E-cadherin, Vimentin, Slug and Twist1 expression; experiments were independently repeated three times. NC, negative control; *p<0.05 vs NC mimic+pcDNA3.1; #p<0.05 vs miR-877-5p mimic+pcDNA3.1.
Fig 2: SSFA2 is a target of miR-877-5p. A) SSFA2 mRNA expression in PCa cell lines; *p<0.05 vs RWPE-1 cells. B) Predicted binding sites of miR-877-5p in SSFA2 3’-UTR. C) Luciferase assay results from miR-877-5p-overexpressed cells transfected with SSFA2-3’-UTR reporter plasmids; *p<0.05 vs NC mimic. D) Verification of the relationship between miR-877-5p and SSFA2 by RNA pull-down assay; *p<0.05 vs Bio-NC; #p<0.05 vs Bio-miR-877-5p WT. E) SSFA2 mRNA and protein levels in PC3 and DU145 cells transfected with miR-877-5p mimic; *p<0.05 vs NC mimic. Experiments were independently repeated three times. WT, wild type.
Supplier Page from Abcam for Anti-KRAP antibody